A vaccine against nicotine for smoking cessation: a randomized controlled trial

Jacques Cornuz, Susanne Zwahlen, Walter Felix Jungi, Joseph Osterwalder, Karl Klingler, Guy van Melle, Yolande Bangala, Idris Guessous, Philipp Müller, Jörg Willers, Patrik Maurer, Martin F Bachmann, Thomas Cerny, Jacques Cornuz, Susanne Zwahlen, Walter Felix Jungi, Joseph Osterwalder, Karl Klingler, Guy van Melle, Yolande Bangala, Idris Guessous, Philipp Müller, Jörg Willers, Patrik Maurer, Martin F Bachmann, Thomas Cerny

Abstract

Background: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period.

Methodology/principal findings: 229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Qbeta (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012).

Conclusions: Whereas Nicotine-Qbeta did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction.

Trial registration: Swiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616.

Conflict of interest statement

Competing Interests: P. Müller, J. Willers, M.F. Bachmann, and P. Maurer are Cytos Biotechnology employees. Cytos employees were involved in the following stages of the trial: 1) study design; 2) immunological assays; 3) data analysis and interpretation; 4) writing process; and 5) decision to submit for publication. The corresponding author had full access to all the data, wrote the manuscript and had final editing rights. S. Zwahlen, Y. Bangala and I. Guessous report no conflict of interest. T. Cerny reports having relevant patent rights. J. Cornuz, T. Cerny, and W.F. Jungi report having received travel expenses fees from Cytos Biotechnology.

Figures

Figure 1. Flow Chart of Study Subjects.
Figure 1. Flow Chart of Study Subjects.
Figure 2. Geometric mean nicotine-specific IgG titers…
Figure 2. Geometric mean nicotine-specific IgG titers (±95% CI) (Active, N = 227; placebo, N = 108).
Figure 3. Nicotine-specific geometric mean IgG titers…
Figure 3. Nicotine-specific geometric mean IgG titers (±95 confidence interval) in the per protocol population (N = 229).
Figure 4. Point prevalence of smoking abstinence…
Figure 4. Point prevalence of smoking abstinence per antibody responder group.
Figure 5. Mean daily number of cigarettes…
Figure 5. Mean daily number of cigarettes smoked by non-abstainers per antibody responder group at the respective visit.

References

    1. Proctor RN. The global smoking epidemic: a history and status report. Clin Lung Cancer. 2004;5:371–376.
    1. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, et al. 2000. Treating Tobacco Use and Dependance: Clinical Practice Guideline (revised 2000)
    1. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev CD000031 2004
    1. Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA, et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther. 1997;283:1076–1081.
    1. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav. 2000;65:191–198.
    1. Cerny EH, Levy R, Mauel J, Mpandi M, Mutter M, et al. Preclinical development of a vaccine ‘against smoking’. Onkologie. 2002;25:406–411.
    1. Malin DH. Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav. 2001;70:551–559.
    1. Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002;69:254–260.
    1. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35:2031–2040.
    1. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, et al. The influence of antigen organization on B cell responsiveness. Science. 1993;262:1448–1451.
    1. Vasiljeva I, Kozlovska T, Cielens I, Strelnikova A, Kazaks A, et al. Mosaic Qbeta coats as a new presentation model. FEBS Lett. 1998;431:7–11.
    1. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002;20:3104–3112.
    1. Ambuhl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25:63–72.
    1. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006;117:1470–1476.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119–1127.
    1. Cornuz J, Humair JP, Seematter L, Stoianov R, van Melle G, et al. Efficacy of resident training in smoking cessation: a randomized, controlled trial of a program based on application of behavioral theory and practice with standardized patients. Ann Intern Med. 2002;136:429–437.
    1. Keyler DE, Hieda Y, St Peter J, Pentel PR. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res. 1999;1:241–249.
    1. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7–16.
    1. Welsch SK, Smith SS, Wetter DW, Jorenby DE, Fiore MC, et al. Development and validation of the Wisconsin Smoking Withdrawal Scale. Exp Clin Psychopharmacol. 1999;7:354–361.
    1. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2007;364:1757–1765.
    1. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.
    1. Hall W. The prospects for immunotherapy in smoking cessation. Lancet. 2002;360:1089–1091.
    1. Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456–467.
    1. Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2004;3:11–18.

Source: PubMed

3
Suscribir